Farringdon Capital Ltd. Acquires New Position in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Farringdon Capital Ltd. bought a new position in shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 4,721 shares of the company’s stock, valued at approximately $426,000.

Other large investors also recently bought and sold shares of the company. Bessemer Group Inc. lifted its stake in iRhythm Technologies by 111.7% during the fourth quarter. Bessemer Group Inc. now owns 568,007 shares of the company’s stock worth $51,217,000 after purchasing an additional 299,726 shares during the last quarter. Stephens Investment Management Group LLC boosted its holdings in shares of iRhythm Technologies by 25.6% in the 4th quarter. Stephens Investment Management Group LLC now owns 502,925 shares of the company’s stock valued at $45,349,000 after buying an additional 102,600 shares during the period. Raymond James Financial Inc. bought a new stake in shares of iRhythm Technologies during the 4th quarter valued at about $9,151,000. Bank of New York Mellon Corp raised its stake in iRhythm Technologies by 23.2% during the fourth quarter. Bank of New York Mellon Corp now owns 491,485 shares of the company’s stock worth $44,317,000 after acquiring an additional 92,591 shares during the period. Finally, Barclays PLC lifted its holdings in iRhythm Technologies by 34.3% in the third quarter. Barclays PLC now owns 209,247 shares of the company’s stock worth $15,534,000 after acquiring an additional 53,498 shares during the last quarter.

Analyst Ratings Changes

Several brokerages recently issued reports on IRTC. Wells Fargo & Company raised their price target on iRhythm Technologies from $86.00 to $104.00 and gave the stock an “equal weight” rating in a report on Friday, February 21st. Oppenheimer boosted their price target on shares of iRhythm Technologies from $105.00 to $120.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. StockNews.com raised shares of iRhythm Technologies from a “sell” rating to a “hold” rating in a report on Monday, February 24th. Truist Financial boosted their target price on shares of iRhythm Technologies from $111.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Finally, The Goldman Sachs Group lifted their price target on iRhythm Technologies from $91.00 to $124.00 and gave the company a “neutral” rating in a report on Monday, February 24th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, iRhythm Technologies has an average rating of “Moderate Buy” and an average price target of $119.73.

iRhythm Technologies Trading Up 1.0 %

Shares of iRhythm Technologies stock opened at $100.96 on Friday. The business has a fifty day simple moving average of $105.57 and a 200-day simple moving average of $93.06. The firm has a market cap of $3.17 billion, a price-to-earnings ratio of -27.74 and a beta of 1.45. iRhythm Technologies, Inc. has a fifty-two week low of $55.92 and a fifty-two week high of $128.52. The company has a quick ratio of 6.12, a current ratio of 6.27 and a debt-to-equity ratio of 9.00.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.30. iRhythm Technologies had a negative net margin of 19.14% and a negative return on equity of 118.83%. The company had revenue of $164.33 million during the quarter, compared to analyst estimates of $158.30 million. On average, equities analysts forecast that iRhythm Technologies, Inc. will post -1.98 EPS for the current fiscal year.

iRhythm Technologies Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.